Ibrexafungerp (Brexafemme) Report issue

Small molecule Approved FDA First in Class Fast Track FDA Priority Review FDA
AACT PubChem

Active Ingredient History

NOW
  • Now

Chemistry

  • SMILES: CC(C)[C@@H](C)[C@@]1(C)CC[C@]2(C)[C@H]3CC[C@@H]4[C@@]5(COC[C@@]4(C)[C@@H](OC[C@](C)(N)C(C)(C)C)[C@H](n4ncnc4-c4ccncc4)C5)C3=CC[C@@]2(C)[C@@H]1C(=O)O
  • InChIKey: BODYFEUFKHPRCK-ZCZMVWJSSA-N
  • Mol. Mass: 730.05
  • ALogP: 8.62
  • ChEMBL Molecules:
    ibrexafungerp  
    ibrexafungerp citrate  
More Chemistry

Pharmacology

Alternative names

scy-078

Organizations (8)

Research & Development (8)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (1)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (13)

Approved Indications (1)


 

Candidiasis, Vulvovaginal (approved 2021)

Experimental Indications - Clinical Trial Phases 1-4 (13)


 

Aspergillosis (Phase 3)

Aspergillosis, Allergic Bronchopulmonary (Phase 3)

Blastomycosis (Phase 3)

Candidemia (Phase 3)

Candidiasis (Phase 3)

Candidiasis, Invasive (Phase 3)

Candidiasis, Vulvovaginal (Phase 3)

Coccidioidomycosis (Phase 3)

Histoplasmosis (Phase 3)

Invasive Pulmonary Aspergillosis (Phase 3)

Mycoses (Phase 3)

Pharmacokinetics (Phase 1)

Vulvovaginitis (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 15
  • # of Trial Organizations: 8

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue